8.14

0.61% -0.05

Pre-market: 8.14

Iovance Biotherapeutics Inc (IOVA)

Overview News Price History Option Chain Financials Why IOVA Down? Discussions Forecast Stock Split

Iovance Biotherapeutics Inc stock is traded at $8.14, with a volume of 5.95M. It is down -0.61% in the last 24 hours and down -20.51% over the past month. Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Previous Close:

$8.19

Open:

$8.21

24h Volume:

5.95M

Relative Volume:

0.99

Market Cap:

$2.48B

Revenue:

$32.77M

Net Income/Loss:

$-440.22M

P/E Ratio:

-3.6339

EPS:

-2.24

Net Cash Flow:

$-400.48M

1W Performance:

-9.56%

1M Performance:

-20.51%

6M Performance:

-21.35%

1Y Performance:

+48.27%

1-Day Range:

$8.05

$8.26

1-Week Range:

$8.05

$9.21

52-Week Range:

$5.14

$18.33

Iovance Biotherapeutics Inc Stock (IOVA) Company Profile

Name

Iovance Biotherapeutics Inc

Sector

Healthcare (1193)

Industry

Biotechnology (683)

Phone

(650) 260-7120

Address

825 INDUSTRIAL ROAD, SAN CARLOS

Employee

557

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

IOVA's Discussions on Twitter

Compare IOVA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IOVA	8.14	2.48B	32.77M	-440.22M	-400.48M	-2.24
VRTX	451.23	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	743.35	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	591.82	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	248.79	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	102.14	24.49B	3.30B	-501.07M	1.03B	11.54

Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-20-23	Initiated	Goldman	Buy
Sep-18-23	Reiterated	Barclays	Overweight
May-30-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Mar-27-23	Resumed	Wells Fargo	Equal Weight
Jan-27-23	Upgrade	Piper Sandler	Neutral → Overweight
Dec-09-22	Downgrade	Goldman	Buy → Neutral
Oct-31-22	Initiated	Guggenheim	Neutral
Aug-18-22	Resumed	Wells Fargo	Equal Weight
Jan-28-22	Upgrade	Stifel	Hold → Buy
Dec-07-21	Resumed	Cowen	Outperform
Jun-10-21	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform
May-20-21	Downgrade	Piper Sandler	Overweight → Neutral
May-19-21	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
May-19-21	Downgrade	Stifel	Buy → Hold
May-03-21	Initiated	Truist	Buy
Apr-16-21	Initiated	Goldman	Buy
Mar-08-21	Upgrade	H.C. Wainwright	Neutral → Buy
Dec-15-20	Downgrade	H.C. Wainwright	Buy → Neutral
Oct-06-20	Downgrade	Wells Fargo	Overweight → Equal Weight
Apr-22-20	Initiated	Mizuho	Buy
Mar-04-20	Initiated	Barclays	Overweight
Feb-26-20	Reiterated	H.C. Wainwright	Buy
Feb-26-20	Reiterated	Oppenheimer	Outperform
Dec-18-19	Initiated	JMP Securities	Mkt Outperform
Oct-01-19	Initiated	Stifel	Buy
Apr-29-19	Initiated	Piper Jaffray	Overweight
Feb-28-19	Reiterated	Chardan Capital Markets	Buy
Feb-07-19	Initiated	Robert W. Baird	Outperform
Dec-31-18	Resumed	B. Riley FBR	Buy
Jul-06-18	Reiterated	Chardan Capital Markets	Buy
Apr-10-18	Upgrade	B. Riley FBR, Inc.	Neutral → Buy
Mar-13-18	Reiterated	B. Riley FBR, Inc.	Neutral
Feb-23-18	Downgrade	B. Riley FBR, Inc.	Buy → Neutral
Jan-25-18	Reiterated	H.C. Wainwright	Buy
Nov-01-17	Reiterated	B. Riley FBR, Inc.	Buy

View All

Iovance Biotherapeutics Inc Stock (IOVA) Latest News

Nov 19, 2024

Long Term Trading Analysis for (IOVA) - Stock Traders Daily

Nov 19, 2024

Nov 15, 2024

Perceptive Advisors LLC's Strategic Acquisition in Iovance Bioth - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

Iovance Biotherapeutics director Maynard sells $503k in stock - Investing.com

Nov 14, 2024

IOVA (Iovance Biotherapeutics) Profitability Rank : 1 (As of Sep. 2024) - GuruFocus.com

Nov 14, 2024

Nov 13, 2024

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

Nov 13, 2024

Iovance Biotherapeutics' SWOT analysis: stock shows promise amid challenges By Investing.com - Investing.com Australia

Nov 13, 2024

Nov 12, 2024

Iovance Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 12, 2024

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Purchased by Principal Financial Group Inc. - MarketBeat

Nov 12, 2024

Nov 11, 2024

Iovance Biotherapeutics Q3: A Beat, But A SelloffNow A Buy Opportunity - Seeking Alpha

Nov 11, 2024

HC Wainwright Has Positive Outlook for IOVA FY2027 Earnings - MarketBeat

Nov 11, 2024

Nov 09, 2024

Earnings call: Iovance reported a third-quarter product revenue of $58.6 million - Investing.com India

Nov 09, 2024

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year - Yahoo Finance UK

Nov 09, 2024

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 09, 2024

Nov 08, 2024

IOVA Posts Narrower-Than-Expected Q3 Loss, Amtagvi Sales Drive Top line - MSN

Nov 08, 2024

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Gap DownTime to Sell? - MarketBeat

Nov 08, 2024